ALPMF - Astellas zolbetuximab resubmission accepted by FDA
2024-05-31 13:04:02 ET
More on Astellas Pharma
- Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
- Astellas Pharma partners with YASKAWA for innovative cell therapy
- Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance
- Historical earnings data for Astellas Pharma
- Dividend scorecard for Astellas Pharma